retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide UK 2026: Phase 3

JACC 75(17):20992106 Patel KHK, Rohin KR, Arunashis S, Pavidra S, Maddalena A, Fu SN (2022) Obesity as a risk factor for cardiac arrhythmias

Medication Safety in Breastfeeding

What happens if someone is undernourished after years of eating a poor diet on these appetite-suppressing drugs and then gets to the point where they can no longer obtain them

While SURPASS-4 was not powered to evaluate differences in MACE-4 incidence between tirzepatide treatment groups and glargine, it was designed to fulfill the MACE-4 non-inferiority analysis requested by regulatory authorities to evaluate the cardiovascular safety of new glucose lowering medications

The broader guide on tirzepatide and autoimmune disease provides additional context

But they sure look like it.